CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc $(BCYC)$ has announced the issuance of inducement awards under its 2024 Inducement Plan, as approved by the Compensation Committee. On June 2, 2025, the company granted non-qualified share options to seven new employees, allowing them to purchase a total of 57,700 ordinary shares. These options come with an exercise price of $8.22 per share, corresponding to Bicycle Therapeutics' closing trading price on May 30, 2025. The vesting schedule spans four years, with 25% of the shares vesting one year after the vesting commencement date and the remainder vesting monthly over the subsequent 36 months, contingent upon continued employment with the company. These awards comply with Nasdaq Listing Rule 5635(c)(4).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.